NeoGenomics Inc. (NG9)
Munich
Closed
Aug 26, 2026
Day's Range
14.2152 wk Range
5.60Overview - NG9 - NeoGenomics Inc.
Key Statistics
Valuation
Enterprise Value
249.83M
P/E (Trailing)
‪-16.92‬
PEG Ratio
‪0.16‬
Price / Book
‪2.34‬
EV / EBITDA
‪-22.84‬
Profitability
Gross Margin
‪45.56%‬
Profit Margin
‪43.21%‬
Operating Margin
‪-14.64%‬
Return on Assets
‪-7.94%‬
Return on Equity
‪-12.91%‬
Ownership
Shares Outstanding
127.91M
Price stats
50-Day Avg
‪12.49‬
200-Day Avg
‪9.72‬
Peers - NG9 - NeoGenomics Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on Munich.
- NG9MunichNeoGenomics Inc.+62.73%52-week change-16.77P/E (Trailing)‪43.21%‬Profit Margin
- 45EMunichNATERA INC (Common Stock) – ticker 45E+55.09%52-week change-125.99P/E (Trailing)‪-9.04%‬Profit Margin
- 1HMMunichAdaptive Biotechnologies Corporation+50.16%52-week change-56.23P/E (Trailing)‪-20.72%‬Profit Margin
- 0MEMunichTwist Bioscience Corporation+80.48%52-week change-93.58P/E (Trailing)‪50.72%‬Profit Margin
- 1K9MunichCareDx Inc.+73.84%52-week change-99.00P/E (Trailing)‪67.55%‬Profit Margin
- 04XMunichPersonalis Inc.+72.42%52-week change-16.38P/E (Trailing)‪22.65%‬Profit Margin
- 5GHMunichGuardant Health Inc.+61.55%52-week change-42.58P/E (Trailing)‪64.46%‬Profit Margin
Profile Summary - NG9 - NeoGenomics Inc.
About
NeoGenomics Inc. is a leading cancer diagnostics company specializing in oncology genetics testing and information services. It offers one of the most comprehensive menus of oncology-focused tests worldwide, including next-generation sequencing (NGS), comprehensive genomic profiling, and advanced assays like RaDaR ST…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
